Citations

Clear

959 citation(s) found for "Service, F J".

Large Symptomatic Splenic Pseudocyst: Case Report of a Rare Entity
Neha, Tasnuva Habib, Mokbul, Mobin Ibne , Yesmin, Farjana , Shrestha, Amrita

Mayo Clinic

Clinical Case Reports | May 2, 2026 | Volume: 14 | Issue: 5 | Pages: No page available

10.1002/ccr3.72584 | PMID 42078048 Get It

ABSTRACT Large symptomatic splenic pseudocysts, though rare, should be considered in patients with persistent left upper abdominal pain as we report in our case. Imaging enables diagnosis, and laparoscopic spleen‐preserving cyst decompression and deroofing provide a safe, effective treatment, relieving symptoms while maintaining splenic function and avoiding the morbidity associated with splenectomy and its long‐term complications.
Widening participation in the International League Against Epilepsy: Looking to the future
Cross, J. Helen , Coleman, Lauren, Oritz, Sebastian, Ivaniuk, Alina, Nome, Cecilie G. , Roza, Eugenia, Shafer, Patricia O. , Gaudecker, Jane von, Ryan, Chris, Brinkmann, Benjamin H. , Neuray, Caroline , Welty, Tim, Wiebe, Samuel , Guekht, Alla, Shafer, Patricia Osborne , Brinkmann, Benjamin H , Cross, Helen J , Ivaniuk, Alina , Roza, Eugenia , Gaudecker, Jane R. von , Wiebe, Samuel , Guekht, Alla B.

Mayo Clinic

Epilepsia Open | April 28, 2026 | Volume: 11 | Issue: 3 | Pages: 719-726

10.1002/epi4.70272 | PMID 42047531 Get It

Abstract The International League Against Epilepsy (ILAE) is a global organization dedicated to improving the lives of people with epilepsy through education, research, and advocacy. Recognizing the need for broader engagement and multidisciplinary collaboration, the ILAE has established five sections: Young Epilepsy Section (YES), Nursing, Social Work and Social Services (SWSSS), Neurotechnology, and Pharmacy. These sections aim to strengthen professional networks, enhance education, and promote innovation in epilepsy care. YES fosters leadership and participation among early‐career professionals, whereas the Nursing Section addresses gaps in epilepsy‐specific training and competency development. SWSSS emphasizes psychosocial care, advocacy, and health equity, supporting Intersectoral Global Action Plan (IGAP) objectives through culturally sensitive interventions. The Neurotechnology section advances the integration and development of innovative tools for diagnosis and treatment, and the Pharmacy section focuses on optimizing medication management and access to antiseizure medications globally. Collectively, these sections contribute to the WHO IGAP by improving policy, care delivery, research, and public health responses. Looking ahead, ILAE seeks to expand multidisciplinary participation, encourage cross‐sectional collaboration, and maintain its role as a leading force in global epilepsy care. Through these initiatives, ILAE continues to build capacity, foster inclusivity, and drive progress toward equitable, comprehensive epilepsy services worldwide. Plain Language Summary The International League Against Epilepsy (ILAE) is the global organization responsible for all healthcare professionals involved in the care of those with epilepsy. Recognizing the increasing number of different disciplines now contributing to epilepsy care, and the need to develop professionals of the future, the ILAE has recognized “sections” of like‐minded individuals to encourage networking and communication. Together, these sections contribute to the WHO Intersectoral Global Action Plan (IGAP) by improving policy, care delivery, research, and public health responses. Moving forward, the ILAE seeks to expand multidisciplinary participation, encourage collaboration, and maintain its role as a leading force in global epilepsy care.
Practical Consensus Recommendations for Polytherapy Involving Stiripentol in Dravet Syndrome: A Nominal Group Approach
Nabbout, R., Gidal, B., Wirrell, E., Cross, H, Sullivan, J., Cross, J. Helen , Cross, Helen J , Nabbout, Rima , Wirrell, Elaine

Mayo Clinic

Neuropediatrics | April 27, 2026 | Volume: 57 | Issue: No issue available | Pages: No page available

10.1055/s-0046-1822873 Get It

COASY-Associated Disorders as a Differential Diagnosis in Cases with Newborn Screening Results Suggestive of CPT-I
Stander, Zinandré, White, Amy , Lynch, Matthew, Rosati, Justin , Bailey, Diana, Johnson, Jessica, Lee, Bo Hoon , Fong, ChinTo, Orsini, Joseph, Schultz, Matthew J, Gavrilov, Dimitar , Matern, Dietrich , Hall, Patricia L., Tortorelli, Silvia , Orsini, Joseph J. , White, Amy L , Lee, Bo Hoon , Orsini, Joseph J , Matern, Dietrich , Tortorelli, Silvia , Stander, Zinandré , Lynch, Matthew , Coman, David , Bailey, Diana, Oglesbee, Devin

Mayo Clinic

International Journal of Neonatal Screening | April 17, 2026 | Volume: 12 | Issue: 2 | Pages: 25

10.3390/ijns12020025 | PMID 42029543 Get It

COASY-related disorders (CRDs) are a spectrum of autosomal recessive conditions caused by the dysfunction of CoA synthase, an enzyme responsible for the final steps of CoA synthesis. Clinical manifestations of CRDs are highly variable, ranging from perinatal lethal pontocerebellar hypoplasia to childhood-onset neurodegenerative brain iron accumulation, which is often recognized after clinical regression. Recent reports have described a few individuals with CRD who screened positive for carnitine palmitoyltransferase-I deficiency by newborn screening (NBS). However, heterogeneous clinical presentations, conflicting biochemical/molecular sequencing of CPT1A, and a lack of metabolic characterization have led to lengthy, costly diagnostic journeys. To address some of these aspects, this investigation retrospectively evaluated NBS acylcarnitine patterns in five CRD cases using Collaborative Laboratory Integrated Reports (CLIR). A total of 25 metabolites/ratios were identified to deviate significantly from reference ranges and were primarily composed of elevated free carnitine and reduced long-chain acylcarnitine levels. While low acylcarnitine concentrations are often not reported due to a lack of lower reference cutoffs, ratios involving these metabolites relative to short-chain acylcarnitines could aid in identifying CRD cases via NBS. When comparing this pattern to CPT-Ia cases, we confirmed a nearly identical acylcarnitine pattern between these, and thus support the need to consider CRD in cases with NBS results suggestive of CPT-Ia. This study is the first case series to characterize NBS patterns in patients with CRD and highlights the unique opportunity for early detection, particularly in cases that are neonatally asymptomatic and have unremarkable confirmatory biochemical results.
Visual and Neurological Outcomes Following Glucagon-Like Peptide-1 Receptor Agonist Therapy and Bariatric Surgery in Idiopathic Intracranial Hypertension: A Network Meta-Analysis
Phutinart, Somkiat , Pajareya, Patavee , Chuanchai, Watsapon , Varama, Abhishet, Anukoolwittaya, Prakit , Thanprasertsuk, Sekh , Roddy, Gavin W. , Pajareya, Patavee , Anukoolwittaya, Prakit , Siranart, Noppachai , Varama, Abhishet

Mayo Clinic

Metabolic Syndrome and Related Disorders | April 13, 2026 | Volume: 24 | Issue: 7 | Pages: 294-303

10.1177/15578518261442833 | PMID 41973746 Get It

Background: Idiopathic intracranial hypertension (IIH) is commonly linked to obesity. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and bariatric surgery may improve outcomes beyond conventional therapy, but comparative evidence is limited. Methods: We systematically searched MEDLINE, EMBASE, and Cochrane from inception until June 2025. Eligible randomized and observational studies compared GLP-1RAs or bariatric surgery (each plus conventional care) against conventional management. Primary outcomes were the change in papilledema, visual acuity, and visual field. Secondary outcomes included body mass index (BMI), retinal nerve fiber layer (RNFL) thickness, monthly headache days, and risks of papilledema, visual disturbance, and headache. Pairwise random-effects meta-analyses and frequentist network meta-analysis ( P -scores) were performed. Results: Out of 429 records, 8 studies were included. Versus conventional therapy, GLP-1RAs reduced BMI (mean difference −1.55 kg/m 2 ; 95% confidence interval [CI]: −2.13 to −0.97) and lowered risks of papilledema (relative risk [RR]: 0.47; 95% CI: 0.34–0.65), visual disturbance (RR: 0.48; 95% CI: 0.24–0.98), and headache (RR: 0.78; 95% CI: 0.69–0.88). Changes in papilledema severity and RNFL thickness were not different; visual acuity favored GLP-1RAs at the end of follow-up, whereas visual field values were worse at some time points. In indirect comparisons with bariatric surgery, no significant differences were detected across outcomes. Conclusions: Adjunctive GLP-1RA therapy may be associated with weight loss and improved clinical/ophthalmic outcomes in IIH relative to conventional care, with a signal for worse visual fields at certain time points. Indirect comparisons suggest comparable efficacy to bariatric surgery. High-quality randomized trials are needed to define comparative effectiveness, safety, and optimal use.
A Val292 substitution combined with an alanine duplication (ADUP) in the Ω loop of ADC β-lactamase confers reduced susceptibility to advanced β-lactam agents, including cefiderocol
Kawai, Akito , McElheny, Christi L. , Shields, Ryan K. , Arias, César A. , Paterson, David L., Patel, Robin , Bonomo, Robert A. , Fowler, Vance G., Doi, Yohei , van Duin, David , Doi, Yohei , Patel, Robin , Bonomo, Robert A , Arias, César A. , Paterson, David L. , Fowler, Vance G.

Mayo Clinic

mBio | April 8, 2026 | Volume: 17 | Issue: 5 | Pages: No page available

10.1128/mbio.03518-25 | PMID 41949313 Get It

ABSTRACT Intrinsic Acinetobacter -derived cephalosporinases (ADCs) in Acinetobacter baumannii are AmpC-type β-lactamases that confer resistance to β-lactam agents, typically through insertion sequence (IS) element-driven overexpression. However, the contribution of ADCs to resistance against advanced β-lactam agents has not been systematically investigated. Given the increasing clinical use of these agents, including cefiderocol, we analyzed the diversity and function of ADC variants in a global collection of carbapenem-resistant A. baumannii (CRAb) isolates. We identified 52 distinct ADC variants in a collection of 428 CRAb clinical isolates from the United States. Among these, variants carrying both a valine substitution at position 292 in the R2 loop and an alanine duplication (ADUP) in the Ω loop consistently conferred stable resistance to cefiderocol. Biochemical and crystallographic analyses demonstrated that ADC-227, which harbors a V292W substitution with an ADUP at position 218a in the Ω loop, exhibits enhanced catalytic efficiencies for ceftazidime and cefiderocol and moderately reduced inhibition by avibactam, leading to resistance not only to cefiderocol but also to ceftazidime–avibactam. Structural studies revealed conformational flexibility of the R2 loop, allowing dynamic accommodation of substrates. Collectively, the findings identify Val292, in combination with an ADUP in the Ω loop, as a mutational “hot spot” for ADCs evolution that may undermine the efficacy of newer β-lactams, including cefiderocol. These results underscore the need for ongoing molecular surveillance of A. baumannii isolates to detect and track the emergence of such variants in clinical settings. IMPORTANCE Carbapenem-resistant Acinetobacter baumannii (CRAb) has been designated as a critical priority pathogen by the World Health Organization (WHO). Cefiderocol has been introduced as a novel therapy against CRAb; however, recent clinical data highlight concerning treatment failures and excess mortality. Understanding resistance mechanisms is therefore essential to preserve the clinical utility of this agent. This study addresses a critical knowledge gap by investigating the role of intrinsic Acinetobacter -derived cephalosporinases (ADCs), which are ubiquitous in A. baumannii and diverse in sequence. By defining specific mutational patterns that endanger cefiderocol activity, this work highlights how chromosomally encoded enzymes can evolve to erode the effectiveness of newer β-lactams such as cefiderocol. These insights underscore the importance of integrating molecular surveillance into clinical practice and antimicrobial stewardship to ensure timely detection of emerging resistance in clinical A. baumannii isolates, ultimately informing treatment strategies and guiding future drug development.
International development of Investigator Global Assessment scores for pemphigus
Murrell, Dédée F., Boucher, Darby , Daneshpazhooh, Maryam, Mahmoudi, H., Kianfar, Nika , Wilson, Anna , BILGIC, ASLI, Chandran, N. S., Patsatsi, Aikaterini , Caux, Frédéric, Lim, Yen L., Marzano, Angelo V., Payne, Aimee S., Sprecher, Eli, Beek, Nina Van, Yamagami, Jun , Antiga, Emiliano, Bagci, I., Borradori, Luca, Caproni, Marzia, De, Dipankar, Dunn, Patrick F. , Feliciani, Claudio, Fivenson, David , Handa, Sanjeev, Horvath, B., Ioannides, D. , Kasperkiewicz, Michael, Lipman, Rachel E. , Mascaró, José M., Meijer, Joost M. , MIMOUNI, D, Schultz, Brittney , Skiljevic, Dusan, Strong, Becky, Tomayko, Mary M. , Vestergaard, Christian , Wozniak, Katarzyna, Yayli, S., Joly, Pascal, Werth, Victoria P., Caproni, Marzia , Joly, P. , Horváth, Barbara , Murrell, D F , Daneshpazhooh, M , Mahmoudi, Hamidreza , Wilson, Anna , Patsatsi, Aikaterini , Drenovska, Kossara , Caux, Frédéric , Marzano, Angelo Valerio , Schmidt, Enno , Sprecher, Eli , Van Beek, Nina , Antiga, Emiliano , Borradori, Luca , Caproni, Marzia , Feliciani, Claudio , Ioannides, Dimitrios , Kasperkiewicz, Michael , Mascaró, José M , Meijer, Joost M , Schultz, Brittney , Vestergaard, Christian , Joly, Pascal , Dasdar, Shayan , Yale, Marc , Uzun, Soner , Vassileva, Snejina , Culton, Donna Aline , Hertl, Michael , Marinović, Branka , Marzano, Angelo Valerio , Payne, Aimee S. , Schmidt, Enno , Sprecher, Eli , Bağci, Işın Sinem , Corrà, Alberto , De, Dipankar , Dunn, Patrick, Günther, Claudia , Handa, Sanjeev , Kowaléwski, Cezary , Lehman, Julia S. , Mimouni, Daniel , Skiljevic, Dusan S. , Woźniak, Katarzyna , Yaylı, Savaş , Werth, Victoria P.

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | April 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/jdv.70430 | PMID 41944632 Get It

Clinical significance of anti‐M in pregnancy and self‐reported ancestry: The BEST collaborative study
Lu, Wen , Ziman, Alyssa , Yan, M. T. S., Virk, Mrigender , Stephens, Laura D. , Radwi, Ghazala, Morrison, Douglas, Marrero‐Rivera, Gisela , Ly, Judy , Ikeda, Kazuhiko, Hands, Katie , Malti, Salwa El, Eichbaum, Quentin , Covello, Thomas, Chang, Shelley, Brancamp, Rachel , Badawi, Maha, AlMozain, Nour, Shan, Hua , Collaborative, The Biomedical Excellence for Safer Transfusion, AlMozain, Nour , Yin, Charles , Yan, Matthew T S , Stephens, Laura , Marrero-Rivera, Gisela , Hasan, Rida A , Clarke, Gwen , Bakhtary, Sara , Badawi, Maha , Ziman, Alyssa , Lu, Wen , Almozain, Nour , Raval, Jay S. , Radwi, Ghazala , Ly, Jane, Juskewitch, Justin E. , Ikeda, Kazuhiko, Hasan, Rida A. , Duncan, Jennifer, Bakhtary, Sara , Au, Nicholas H. C.

Mayo Clinic

Transfusion | April 6, 2026 | Volume: 66 | Issue: 6 | Pages: 1086-1098

10.1111/trf.70210 | PMID 41937612 Get It

Abstract Background Anti‐M antibodies were described as rarely eliciting hemolytic disease of the fetus and newborn (HDFN) in pregnancy. More recent literature, primarily from Asia, reports severe HDFN attributed to maternal anti‐M. The objective of this study is to determine if there is a difference in the frequency and/or severity of anti‐M HDFN among subjects who self‐report as Asian compared to non‐Asian. Methods Retrospective data were collected from 18 sites. Fetuses/neonates affected by HDFN were categorized as unaffected, mild, moderate, or severe based on clinical management and outcomes. Results Anti‐M was identified in 557 obstetric patients. Among 332 neonates with complete data for analysis, anti‐M was detected in isolation during the pregnancies of 210 (63.3%) neonates; 198 (94.3%) were unaffected by HDFN. The overall frequency of HDFN was 6.5% (2/31) in Asian patients and 5.6% (10/179) in non‐Asian patients. The frequency of severe HDFN was 6.5% (2/31) among Asian patients and 0.6% (1/179) among non‐Asian patients. Among non‐Asian patients, eight (4.5%) were mild and one (0.6%) was moderate. Of 63 pregnancies with anti‐M and ABO incompatibility, 6 (9.5%) were associated with mild HDFN and 57 (90.5%) were unaffected. Of 49 pregnancies with anti‐M and non‐ABO antibody(s), 6 (12.2%) were associated with mild HDFN and 43 (87.8%) were unaffected. One case (10.0%) of HDFN (mild) occurred in the presence of anti‐M, additional antibody(s), and ABO incompatibility. Conclusion In this study, severe anti‐M HDFN was rare in non‐Asian subjects. There is a signal that Asian patients are at greater risk for severe anti‐M HDFN.
Consensus recommendations for malignant histiocytic neoplasms (histiocytic, Langerhans, and interdigitating dendritic cell sarcomas)
Goyal, Gaurav, Abla, Oussama , Chan, John K. C. , Diamond, Eli L. , Durham, Benjamin H. , Emile, J, Girschikofsky, Michael , Go, Ronald S., Jaffe, Elaine S. , Go, Ronald S. , Emile, Jean‐François , Goyal, Gaurav , Goyal, Guarav , Chan, John , Durham, Benjamin , Emile, Jean-François , Go, Ronald S , Hornick, Jason L , Jaffe, Elaine S , McClain, Kenneth L , Picarsic, Jennifer L , Diamond, Eli L , Hornick, Jason L. , McClain, Kenneth L. , Rech, Karen L. , Picarsic, Jennifer

Mayo Clinic

Blood | March 31, 2026 | Volume: 148 | Issue: 3 | Pages: 275-288

10.1182/blood.2026033049 | PMID 41915766 Get It

Abstract Malignant histiocytic neoplasms (MHNs) are rare tumors derived from the mononuclear phagocyte system (MPS), encompassing histiocytic sarcoma, Langerhans cell sarcoma, interdigitating dendritic cell sarcoma, and other high-grade MPS lineage tumors. Despite advances in understanding histiocytic neoplasms, MHNs remain diagnostically challenging and lack standardized treatment algorithms. Current classification systems differ in lineage framing and fail to address mixed or ambiguous phenotypes, contributing to diagnostic uncertainty and inconsistent care. To address these gaps, the Histiocyte Society convened an international working group of pathologists and oncologists, including World Health Organization and International Consensus Classification contributors, to harmonize nomenclature, define minimum diagnostic criteria, and develop pragmatic treatment recommendations. Using a modified Delphi process and case-based review, the group formulated >40 consensus statements spanning classification, pathology, molecular testing, clinical evaluation, and therapeutic strategies. Key recommendations include the adoption of a unified MHN designation, use of a minimum immunophenotypic panel, integration of broad molecular profiling, and the documentation of previous hematopoietic malignancy. Treatment algorithms emphasize surgical resection for unifocal disease and targeted therapy or immune checkpoint inhibition for multifocal disease when actionable mutations or programmed death ligand 1 expression are present. These consensus recommendations aim to reduce diagnostic ambiguity, standardize reporting, and improve outcomes for both pediatric and adult patients. Future priorities include international registries to refine risk stratification and biomarker-driven trials exploring targeted therapy, immunotherapy, and combination approaches.
Content validation of a pre-treatment oral oncolytic non-adherence estimator (ORACLE)
Muluneh, Benyam , Sirek, Marie E. , Imam, Tahsin, Diaz-Rohena, Yarelis, Tran, Thuy, Taraba, Jodi L. , Darling, Julianne O. , Taraba, Jodi, Taraba, Jodi L

Mayo Clinic

Journal of Oncology Pharmacy Practice | March 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/10781552261435203 | PMID 41914803 Get It

Background Oral anti-cancer treatment is commonly used, and non-adherence can negatively affect outcomes. The Oral Oncolytic Non-Adherence Estimator (ORACLE) was designed to prospectively categorize patients into risk levels by considering constructs such as self-efficacy, health literacy, perception of treatment, quality of life, social support, and regimen complexity. Validating this estimator is essential. Methods A content validation survey evaluated representativeness, clarity, and factor structure of each construct in ORACLE. A multidisciplinary panel of 8 content experts and 4 lay experts completed the survey. Results were analyzed to evaluate inter-rater agreement, content validity index (CVI), and factorial validity index (FVI). Post-survey workgroup discussions reviewed results and considered tool adjustments. Results All 12 invited experts completed the survey. The average CVI for content experts was 0.88 for representativeness and 0.98 for clarity. The average CVI for lay experts was 0.95 for clarity. The average FVI was 0.88, with self-efficacy and negative perception constructs yielding the lowest scores (0.63 and 0.75, respectively). ORACLE revisions addressed survey results and expert feedback on health literacy, social support, and regimen complexity. Conclusions Strong CVI for content and lay experts (94% and 95%) and strong FVI for content experts (98%) verify that the tool is understandable and addresses non-adherence issues, establishing validity of construct clarity and representativeness. Content validity of the first pre-treatment oral oncolytic non-adherence risk estimator was established, providing a reliable tool to identify patients at higher risk of non-adherence.